New Data on BerGenBio’s Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting
BERGEN, Norway, October 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer (NSCLC) were presented during the European Society of Clinical Oncologists (ESMO) Annual Meeting 2023. The poster presentation is now available on BerGenBio’s website under →Pipeline→Scientific Publications. In addition, on October 21st, Dr. Oddbjorn